MediWound Ltd. reported total revenue of $3.96 million for the first quarter ended March 31, 2025, a decrease from $4.96 million in the prior year. The company posted a net loss of $0.73 million, or $0.07 per share, which is a significant improvement from a net loss of $9.73 million, or $1.05 per share, in Q1 2024.
The company reaffirmed its full-year 2025 revenue guidance at $24 million. MediWound also confirmed that the VALUE Phase III study for EscharEx is on schedule and that NexoBrid manufacturing expansion is on track for full operational capacity by year-end 2025.
As of March 31, 2025, MediWound held $38.7 million in cash, cash equivalents, and deposits. The company used $5.1 million to fund operations during the first quarter of 2025, reflecting ongoing investments in its pipeline and manufacturing capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.